secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmonx Corp (LUNG)
CIK:        0001127537
Form:       8-K/A
Filed at:   2022-02-25T23:59:59+00:00
Accession:  0001127537-22-000009
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmonx Q4 revenue $13.7M (+39% YoY); FY2022 guidance $55M-$60M
---------------------------------------------------------------

- Q4 2021 revenue $13.7M, up 39% YoY; FY2021 revenue $48.4M, up 48% YoY.
- Gross margin improved to 74.8% in Q4 and 73.6% for FY2021, vs 72.0% and 64.8% a year ago.
- Net loss Q4 $13.0M ($0.35/sh); FY net loss $48.7M ($1.35/sh).
- FY2022 revenue guidance $55M-$60M; Q1 2022 guidance $9M-$10M, reflecting COVID impact.
- U.S. treatment centers for Zephyr Valves expanded to 214, up 45% from start of 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1127537/000112753722000009/0001127537-22-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1127537/000112753722000009/lung-20220223.htm
  HTML page:      https://secwatch.observer/filing/0001127537-22-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer